ECM
JAZZ icon

Element Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Element Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-44,492
Closed -$5.76M – 115
2023
Q3 		$5.76M Sell
44,492
-4,423
-9% -$589K 0.51% 53
2023
Q2 		$6.06M Buy
+48,915
New +$6.58M 0.41% 54
2019
Q2 		– Sell
-11,614
Closed -$1.66M – 487
2019
Q1 		$1.66M Buy
11,614
+4,071
+54% +$531K 0.05% 283
2018
Q4 		$935K Buy
+7,543
New +$1.12M 0.03% 315

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Element Capital Management's JAZZ Position: Q4 2023 in Review

Element Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2023, closing a stake of 44,492 shares — an estimated $5.76M sold.

Element Capital Management first reported a position in JAZZ in Q4 2018 and held it in 4 quarters. The position peaked at $6.06M in Q2 2023. 500 funds tracked by Wall St. Rank hold JAZZ as of Q4 2023.

  • Element Capital Management reported no remaining Jazz Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Element Capital Management sold 44,492 Jazz Pharmaceuticals shares in Q4 2023, an estimated $5.76M.
  • Element Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 4 quarters.
  • Element Capital Management's Jazz Pharmaceuticals position peaked at $6.06M in Q2 2023.
  • 500 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2023.

Based on Element Capital Management's 13F filing for Q4 2023, filed 9 Feb 2024.